• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

FDA's Criminal Investigation Head to Leave as Trump Takes Office

Article

January 04, 2017

Reuters reports that George Karavetsos, director of the Food and Drug Administration's Office of Criminal Investigations (OCI), is to leave the agency.   Karavetsos has been OCI director since January 2015. The report adds that Karavestos's "last day will be Jan. 20, the day Donald Trump is sworn in as president".   http://www.reuters.com/article/us-usa-fda-moves-idUSKBN14N1SA  

Related Videos
Related Content
Abid Rahman

Will Synthetic, AI-Based Digital Humans Change Pharma and Life Sciences? Q&A with Abid Rahman, SVP Innovation, EVERSANA

April 19th 2024
Article

Rahman discusses the new opportunities that digital twins present to researchers.

UniDoc

UniDoc Brings AI-Powered Health Cube to Alaska

April 17th 2024
Article

The Health Cube will increase remote and virtual care options for populations living in remote areas.

Riccardo Butta

At-Home Patients and AI: Q&A with Riccardo Butta

April 16th 2024
Article

Butta discusses how new technologies are being implemented in at-home devices.

Say Hello to Flexible: Reimagining the Patient Journey

Say Hello to Flexible: Reimagining the Patient Journey

April 15th 2024
Article

Through embracing connected and tech-enabled services and devices, new avenues and opportunities exist for greater clinical trial flexibility in drug research.

Stock.adobe.com

ArisGlobal Announces Second Life Sciences Generative AI Council Session

April 11th 2024
Article

The meeting is scheduled for May in Switzerland.

Image credit: ArtemisDiana | stock.adobe.com

Precision Medicine: Investments and Outcomes Expected

March 18th 2024
Article

Precision medicine is now seen as a healthcare approach for both the present and the future, particularly with the explosion of personalized care delivery.